OCTIMET Oncology NV

OCTIMET Oncology is a biotechnology startup based in Belgium, specializing in the development and distribution of oral cancer medication OMO-1. Founded in 2016 by Dr. Timothy Perera (CEO), the company has made significant strides in the field of oncology. OCTIMET has partnered with Shanghai Allist and DeuterOncology to bring their innovative products to the market.

Under the leadership of Dr. Timothy Perera, OCTIMET has secured a €1.08M grant investment from Agentschap Innoveren & Ondernemen in August 2018. The company's focus on advancing the development of highly selective MET kinase inhibitors and employing innovative patient selection and pharmacodynamic biomarker-based strategies demonstrates its commitment to pioneering solutions in cancer therapeutics. This approach aims to differentiate OCTIMET's offerings and positioning within the current treatment paradigms, setting them apart from competitors.

OCTIMET's collaboration with pharmaceutical giant Janssen Pharmaceutica and its use of cutting-edge clinical development strategies showcase the potential for impactful and groundbreaking advancements in cancer treatment. With a strong emphasis on intelligent patient selection through biomarker-defined approaches, the company is poised to make significant contributions to the oncology industry.